Key information

🔎 Fund Overview

Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. Emavusertib, its lead clinical-stage drug candidate, is an orally available small molecule drug candidate that is designed to inhibit the Interlukin-1 receptor associated kinase 4 (IRAK4) kinase, which is an important transducer of toll-like receptor or certain interleukin receptor signaling pathways. Erivedge is an orally bioavailable small molecule, which is designed to selectively inhibit the Hedgehog signaling pathway by targeting a protein called Smoothened. Its other programs include CI-8993, Fimepinostat, CA-170 and CA-327. CI-8993 is a human IgG1 kappa monoclonal antibody directed against the VISTA protein. CA-170 is an oral small molecule drug candidate that is designed to selectively target VISTA and PDL1 immune checkpoint proteins. The Company conducts its research and development programs both internally and through strategic collaborations.